Curasan AG

ots Ad hoc-Service: curasan AG curasan AG (WKN 549 453) today announced that it has exceeded its projected results in the first two quarters of 2000

The sender is solely responsible for the contents of this announcement. -----------------------------------------------------

    Kleinostheim (ots Ad hoc-Service) - curasan AG (WKN 549 453), a leading specialist in regenerative medicine, today announced that it has exceeded its projected results in the first two quarters of 2000. The EBIT showed a marked improvement at DM -1.6 million, up from DM -2.2 million. Despite substantial sales and marketing investments, especially for the bone regeneration material Cerasorb, the EBIT was also better than anticipated. In relation to the total turnover, the EBIT improved to -17.8% (-33.3% in the first two quarters of 1999). curasan, which has been quoted on the Neuer Markt of the Frankfurt Stock Exchange since 20 July 2000, was able to increase its turnover in the first half of 2000 by 47.9% to DM 10.3 million, up from DM 7.0 million. The net loss decreased from DM -2.4 million to DM -2.2 million. Thanks to its highly qualified sales force, curasan AG ranks among the companies with the greatest marketing power in the growth market for pharmaceutical products and biomedicine. With its synthetic bone regeneration material Cerasorb, curasan has positioned itself at the top of the growth market for bone regeneration.

    The bone regeneration material Cerasorb and complementary products for controlled and accelerated bone regeneration have contributed significantly to the high increase in turnover. Overall, the Biomaterials segment, driven by the growth in products for the treatment of bone defects, grew by 105% to DM 3.1 million, up from DM 1.5 million. The Biologicals segment, especially biological pharmaceuticals, doubled its turnover from DM 0.5 million to DM 1.0 million. Thus, these two young sectors achieve a turnover of DM 4.1 million (DM 2.0 million), contributing 39.8% (28.6%) to the company's total turnover. Due to the dynamic growth witnessed during the first six months of the current financial year, the projected turnover share of 47%, which was planned for the entire year, has almost been reached by mid-year. In 2001, curasan plans to realize 65% of its total turnover with innovative Biomaterials and Biologicals products.

    Furthermore, curasan has been able to enter new markets, thus expanding the international scope of its business, which is yet another growth factor for the company. Foreign turnover more than doubled to DM 1.5 million, up 108% from last year's DM 0.7 million.

      Due to the expansion of the company's sales/marketing and
research staff, the number of employees increased to 88 (56). The
specialized dental products sales force will continue to expand
curasan's strong position in dental surgery and drive the
establishment of Cerasorb as the global standard in bone
regeneration. Personnel expenses went up to DM 4.3 million (DM 2.8
million). Material expenses rose to DM 4.3 million (DM 3.1 million).
Relative to the total turnover, the cost of goods purchased decreased
to 41.6% (45.0%), despite the strong dollar which impacted the
purchase of some raw materials. The increase of operating expenses to
DM 3.7 million (DM 3.2 million) was clearly below average. (More

curasan AG Der Vorstand

    End ----------------------------------------------------- Internet:

Original-Content von: Curasan AG, übermittelt durch news aktuell

Weitere Meldungen: Curasan AG

Das könnte Sie auch interessieren: